Scientists are mining the DNA-sequence data from mushrooms and mold to find new drugs
Maureen Hillenmeyer doesn’t know exactly what’s growing in her incubators, but she has high hopes. The rectangular plates in the backroom of Hexagon Bio are heated to 86F and filled with yeasts unlike any other. The fungal microorganisms have been painstakingly outfitted with custom- printed DNA parts that give ordinary baker’s yeast the capacity to make new compounds that could potentially cure disease. “When we know it’s making a molecule, then we go in and say, ‘Is that molecule doing something interesting to cancer cells?’ ” says Hillenmeyer, co-founder and chief executive officer of Hexagon, based in Menlo Park, Calif. “That’s the real field testing.”
The company’s approach to drug discovery is half computation, half biology. A team of data scientists uses proprietary algorithms to mine a trove of data extracted from the DNA sequences of more than 2,000 species of mushrooms and molds, known as the fungal genome. Hexagon then predicts which strings of DNA, or gene clusters, are most likely to produce specific types of chemical compounds. If all goes according to plan, the yeasts will generate about 100 compounds that are particularly lethal to certain types of cells and proteins, making them the sturdy foundations of new treatments for infectious diseases and cancer. As Hillenmeyer walks through an adjacent lab, she leans over to check on Anton— the robot that handles the liquid DNA—and notices an acrid aroma, one of the few signs of the process. “It’s a little fragrant today,” she says.
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Golfing With The Enemy
Did Donald Trump's executives violate the Cuban embargo?
Super-Rich Syrians Wait for War's End
Actor, author, playwright. Gill Pringle tries her hand at unravelling the mystery behind this enigmatic multi-hyphenate
Pam Codispoti
The mastermind behind the industry-shaping Chase Sapphire Reserve Card sets her sights on banking
This Time It's The Economy
President Rouhani’s budget sets offprotests from people angry about unemployment and inflation
Saudi Prince Counts On Support Of Citizens
State-worker salary increases appeal to the people, but policy may throw the budget off track
Stalin's Legacy Is Choking The Ukrainian Economy
The government has resisted pressure to lift a ban on land sales, despite pressure from the IMF and investors
Catastrophe Bonds Survive A Stormy Year
The turbulence of 2017 couldn’t destroy a market for betting against disasters
Riding The West Bank's Credit Boom
Increased consumer lending is creating a bubble in the West Bank
You'd Be Crazy To Buy Pizza With Bitcoin
Speculative fervour makes the cryptocurrency clumsy for commerce
What If The President Loses His Party?
Trump has to figure out a way to work with Republicans in Congress, or the global economy may be at stake